Phaseline

Targets › SGCG

SGCG (Gamma-sarcoglycan): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jan 2031.

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. (UniProt, Q13326)

Open in Phaseline: the race on SGCG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Atamyo TherapeuticsATA-200
SGCG gene replacement therapy
SGCGPhase 1LGMD2CJan 2031

Conditions

LGMD2C (1)

Modalities

protein or peptide (1)

Companies

Atamyo Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.